NO20016053L - IL-8 reseptor-antagonister - Google Patents

IL-8 reseptor-antagonister

Info

Publication number
NO20016053L
NO20016053L NO20016053A NO20016053A NO20016053L NO 20016053 L NO20016053 L NO 20016053L NO 20016053 A NO20016053 A NO 20016053A NO 20016053 A NO20016053 A NO 20016053A NO 20016053 L NO20016053 L NO 20016053L
Authority
NO
Norway
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016053A
Other languages
English (en)
Other versions
NO20016053D0 (no
Inventor
Katherine Louisa Widdowson
Daniel Frank Veber
Anthony Joseph Jurewicz
Melvin C Rutledge
Robert Philip Hertzberg
Gregory Martin Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016053L publication Critical patent/NO20016053L/no
Publication of NO20016053D0 publication Critical patent/NO20016053D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
NO20016053A 1999-06-16 2001-12-11 IL-8 reseptor-antagonister NO20016053D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16
PCT/US2000/016499 WO2000076495A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016053L true NO20016053L (no) 2001-12-11
NO20016053D0 NO20016053D0 (no) 2001-12-11

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016053A NO20016053D0 (no) 1999-06-16 2001-12-11 IL-8 reseptor-antagonister

Country Status (20)

Country Link
EP (1) EP1185261A4 (no)
JP (1) JP2003501459A (no)
KR (1) KR20020010709A (no)
CN (1) CN1355697A (no)
AR (1) AR030391A1 (no)
AU (1) AU766083B2 (no)
BR (1) BR0010802A (no)
CA (1) CA2377341A1 (no)
CO (1) CO5200760A1 (no)
CZ (1) CZ20014471A3 (no)
HK (1) HK1044483A1 (no)
HU (1) HUP0201571A3 (no)
IL (1) IL145761A0 (no)
MX (1) MXPA01013004A (no)
NO (1) NO20016053D0 (no)
NZ (1) NZ514695A (no)
PL (1) PL352232A1 (no)
TR (1) TR200103680T2 (no)
WO (1) WO2000076495A1 (no)
ZA (1) ZA200109479B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
KR20050026091A (ko) * 2002-08-01 2005-03-14 뉴로서치 에이/에스 항혈관형성 요법에 반응하는 질환의 치료에 유용한 화합물
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
AU2005299771A1 (en) 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
JP2008543972A (ja) 2005-06-27 2008-12-04 ブリストル−マイヤーズ スクイブ カンパニー 血栓症状の治療に有用なｐ２ｙ１受容体のｎ−結合複素環式アンタゴニスト
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (ja) * 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
KR100982661B1 (ko) * 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
KR100970940B1 (ko) * 2010-05-03 2010-07-20 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법
US10093617B1 (en) 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO2000016768A1 (en) * 1998-09-18 2000-03-30 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
IL145761A0 (en) 2002-07-25
AU766083B2 (en) 2003-10-09
NO20016053D0 (no) 2001-12-11
HK1044483A1 (zh) 2002-10-25
CZ20014471A3 (cs) 2002-08-14
JP2003501459A (ja) 2003-01-14
TR200103680T2 (tr) 2002-07-22
PL352232A1 (en) 2003-08-11
HUP0201571A2 (en) 2002-08-28
CN1355697A (zh) 2002-06-26
WO2000076495A1 (en) 2000-12-21
KR20020010709A (ko) 2002-02-04
BR0010802A (pt) 2002-02-19
EP1185261A1 (en) 2002-03-13
HUP0201571A3 (en) 2002-11-28
MXPA01013004A (es) 2002-07-30
AU5741300A (en) 2001-01-02
CA2377341A1 (en) 2000-12-21
EP1185261A4 (en) 2004-02-25
AR030391A1 (es) 2003-08-20
CO5200760A1 (es) 2002-09-27
NZ514695A (en) 2004-05-28
ZA200109479B (en) 2002-11-18

Similar Documents

Publication Publication Date Title
NO20001100D0 (no) IL-8 reseptorantagonister
NO20025754D0 (no) IL-8 Reseptor-antagonister
ATE346043T1 (de) Il-8-rezeptorantagonisten
NO20016053D0 (no) IL-8 reseptor-antagonister
ATE299698T1 (de) Il-8 rezeptor antagonisten
DK1261336T3 (da) IL-8-receptorantagonister
NO20016052L (no) IL-8-reseptor-antagonister
ATE381330T1 (de) Il-8 rezeptor-antagonisten
MA25739A1 (fr) Antagonistes recepteurs il-8
DK1180028T3 (da) IL-8-receptorantagonister
DE69831413T2 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20015774L (no) IL-8 reseptorantagonister
MA25659A1 (fr) Antagonistes recepteurs il-8
NO20016102D0 (no) IL-8 reseptorantagonister
NO20016065L (no) IL-8-reseptor-antagonister
NO20024366D0 (no) IL-8 reseptorantagonister
NO20010353D0 (no) IL-8 reseptor-antagonist
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application